Arcutis Biotherapeutics director sells 10,000 shares under 10b5-1 plan

A director of Arcutis Biotherapeutics sold 10,000 shares of the company on April 1, 2026, for a total transaction value of $239,000, according to an SEC Form 4 filing.

The sale reduced the director’s direct common stock holdings by 20.10%, bringing the position down from 49,744 shares to 39,744 shares. The filing indicates the transaction involved only direct ownership, with no indirect entities or derivative securities implicated.

Transaction details

• Shares sold (direct): 10,000
• Transaction value: $239,000
• Post-transaction shares (direct): 39,744
• Post-transaction value (direct ownership): $958,000

The transaction value was based on the SEC Form 4 reported price of $23.88. The post-transaction value was based on the trade-date market close price.

Context and scale of the sale

The 10,000-share sale aligns with the director’s typical monthly trading cadence observed since 2023, with prior individual sale sizes ranging from 9,208 to 10,139 shares.

In percentage terms, the transaction represented about 20% of the director’s direct common stock holdings before the sale. After the transaction, the remaining position of 39,744 shares corresponds to roughly 14.3% of the starting holdings from two years prior, indicating reduced capacity for future sales at a similar scale.

Company snapshot

• Price (market close, 2026-04-01): $23.88
• Market capitalization: $2.89 billion
• Revenue (TTM): $376.07 million
• 1-year price change: 65%

Business overview

Arcutis Biotherapeutics develops and commercializes topical therapies for dermatological diseases, including plaque psoriasis, atopic dermatitis, seborrheic dermatitis, scalp psoriasis, hand eczema, vitiligo, and alopecia areata.

The company generates revenue through the development, approval, and commercialization of proprietary prescription treatments, primarily leveraging its lead product candidates ARQ-151 (roflumilast cream) and ARQ-154 (roflumilast foam). It focuses on dermatologists and healthcare providers treating patients with chronic inflammatory skin conditions in the United States and select international markets.

Implications for investors

The SEC filing indicates the sale was executed as part of a structured liquidity program under a 10b5-1 plan adopted in March 2025, rather than reflecting a reactive change in conviction.

Beyond the insider activity, the company’s commercialization progress is highlighted in the original reporting. Arcutis generated $372.1 million in net product revenue in 2025, up 123% year over year, with fourth-quarter sales of $127.5 million. The report also notes improving financial quality, including positive operating cash flow in Q4 and expectations to sustain it.

On the clinical side, the original content cites Phase 2 data for ZORYVE cream in infant atopic dermatitis, including rapid itch relief and strong tolerability, supporting a planned regulatory submission in 2026.